real-time news and commentary for investors
Wednesday, Aug 1
2012, 12:05 PM
Sublingual immunotherapy, a liquid treatment for allergies taken under the tongue, is becoming...
Sublingual immunotherapy, a liquid treatment for allergies taken under the tongue, is becoming increasingly popular as an alternative to traditional allergy shots. While not yet approved by the FDA, the treatment could be a boon for the company that gets there first, and there are at least three companies, including heavyweight Merck (MRK +1%), that are funding large U.S. studies aimed at getting it approved in the next few years.